Friday AH ask was at 1.75 now 1.9... looks like recovering comming this week. I can't believe a stock can drop 30% just beceause 1 man is telling lies on internet. They should sue AF.
Fridays article just doesn't matter... This week was just a little correction after great gains the article just scared some extra and uninformd investors. CPRX will recover in the next weeks and find new hights. Traget going higher and higher, last week under 4 dollar weekend 4,16 today 4,33... By the end of the year Cprx will trade over 5 dollar. Glta
yes, but there was almost no volume... 100,000 shares. And who cares about those criminal lawfirms?
down from 1.91 close to 1.75 on 100,000 shares... how and why did this happen? CPRX traded 9.8 million shares on Friday down 27% and then down 10% AH on 100,000 shares. CRAZY... looks like manipulation, just like the article. Up on Monday.
PPS target by analysts keeps moving up. Last week it was still under 4dollar. it went up to 4.16 and now 4.33. Hope to see us get back over 2.5 this week. gltal
Feuerstein graduated from Emory University with a bachelor's degree in political science.
In conclusion, Catalyst appears to be an excellent speculation for significant price appreciation based on comparison to Aegerion and Acadia, and also based on the high likelihood of Firdapse being approved by the FDA in 2015. If Catalyst matches the performance of Aegerion and Acadia, and if market conditions remain stable, shares have the potential to appreciate to $41.66 in 12 to 18 months.
bump, that's what i am thinking to. The product can stay on the market and they can still use it for what they are using it now. ARIA will still have the income from the product. It would have been much worse when FDA took the product off the market. i realy don't get the reaction today.
So ARIA will change the label of iclusin and the product can stay on the market for what it is used now... Isn't that good news? on the other hand they will stop further trails to use Iclusin for other groups of patients? Isn't that already calculated in the PPS? If they say Iclusin will stay on the market we only have to change the label, isn't that good news? I don't get it. They halt the phase 3 study, but on the other hand Iclusin WILL STAY ON THE MARKET.
Iclusig is commercially available in the U.S. and EU for patients with resistant or intolerant CML and Philadelphia-chromosome positive acute lymphoblastic leukemia. ARIAD continues to work with health authorities to make appropriate changes to the Iclusig product labeling to reflect the recently announced safety findings from the pivotal PACE trial that was the basis of its marketing approvals.
And where did you saw that. Give me some stocks? I think you are wrong. Most of the time bio-stocks like ARIA get a huge overreaction on the sell side. After a bounce in day one the stock goes down to the first made low and then starts it's way up to a fair price. For ARIA a fair price would be around 10 dollar imo. Stop posting with no background. Are you long or short and at what price?